Last reviewed · How we verify
NCT05712005: FOCUS
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
trial in Cognitive Change in 1,437 participants. Completed in 23 December 2022.
23 December 2022
Quick facts
| Lead sponsor | Cognivue, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,437 |
| Start date | 8 September 2022 |
| Primary completion | 23 December 2022 |
| Estimated completion | 23 December 2022 |
| Sites | 1 location across United States |
Conditions studied
- Cognitive Change — all drugs for Cognitive Change →
Sponsor
Cognivue, Inc.
Who can join
18 and older, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label, multi-site, validity and reliability study to obtain data on the Cognivue 5-Minute Screening and Cognivue 10-Minute Assessment tests to assess scoring and normative ranges and compare against other cognitive tests within a diverse population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05712005
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Change
Currently open trials in the same condition.
- NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
- NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
- NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
- NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
- NCT07054723 — Surviving Daily Life · recruiting
Other Cognivue, Inc. trials
Trials by the same sponsor.
- NCT04950673 — Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05712005 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cognivue, Inc.
- Last refreshed: 3 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05712005.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing